Reported Earnings • May 14
First quarter 2026 earnings released First quarter 2026 results: US$0.14 loss per share. Net loss: US$962.9k (loss widened 228% from 1Q 2025). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Apr 24
Vyome Holdings, Inc. Presents Transformational VT-1953 Phase 2 Clinical Study Data Vyome Holdings, Inc. presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, on April 21, 2026. VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015). 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle (control arm) reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14 (P= 0.0256). Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 (p= 0.0020) as scored using a 10-point VAS scale. No change seen in vehicle-treated arm. No treatment-emergent adverse effects were reported in this Phase 2 study. MFWs are non-healing wounds that occur in ~10% of advanced cancer patients (~65,000 patients in the U.S. alone each year). Patients suffer symptoms such as severe ‘rotten meat’ malodor, pain, which negatively impacts quality of life. There are currently no FDA approved drugs to treat these symptoms of MFW. Vyome is developing VT-1953 as a first in class treatment for symptoms of MFW. VT-1953 acts by dual mechanism of action, inhibiting DNA Gyr and modulating MD2/TLR interactions, an inflammatory signal. In the Ph2 study, advanced cancer patients with MFW who scored at a median 0.5 (corresponding to extreme malodor that is detected 6-10ft away with dressing on) at start of treatment with VT-1953 improved (P=0.0020) to a median score of 4 (mild odor detectable up close only after removing dressing) by Day 14 on a TELER scale of 0-5 scored by clinical investigator (Primary endpoint). MFW patients treated with the vehicle as a control arm showed no improvement in malodor (median score remained the same on Day 14 as Day 1; P=0.9999). VT-1953 treatment was significantly superior to the control arm (P = 0.0015). On a secondary endpoint, where patients were asked to score the impact of malodor on their life, 70% of patients treated with VT-1953 reported an improvement to a score range of 3 to 5 by Day 14 from a baseline score of 0, as compared with 0% of patients in the vehicle-treated arm (P = 0.0256). Patients were also asked to score the level of malodor on a 10-point visual analog scale, where 0 was no smell, while 10 was the worst smell. Treatment with VT-1953 gel treatment group improved the median score from 7.5 at the start of treatment to 2.5 by Day 14, a significant improvement (p=0.0020) from baseline. Patients treated with the vehicle reported an increase (worsening) in median malodor score from 6.0 at baseline to 7.0 by Day 14 (p=0.0625). Patients treated with VT-1953 also reported a clinically significant 2-point improvement in lesion pain by Day 14 (p= 0.0020) as scored using a 10-point VAS scale, while patients treated with vehicle reported no improvement from baseline score. Treatment did not change exudate levels. There were no treatment-associated adverse effects reported. Tillkännagivande • Apr 07
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 Vyome Holdings, Inc. announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. The research will be presented at the session “Phase II and Phase III Clinical Trials in Progress.” Vyome will highlight mechanistic insights together with detailed clinical data comparing the VT-1953 active treatment with vehicle treatment in a Phase 2 study. VT-1953 is a first-in-class treatment for malodor and other symptoms of MFW in advanced cancer patients, which acts by a dual mechanism of action, inhibiting DNA Gyr and modulating MD2/TLR interactions, an inflammatory signal. MFW is a rare, debilitating condition that occurs in ~10% of advanced cancer patients, severely impacting the quality of life. The details of the presentation at the 2026 AACR Annual Meeting are: American Association for Cancer Research Annual Meeting 2026, San Diego. Date: April 21, 2026, 9:00 AM - 12:00 PM. Session title: (PO.CTP01.03) Phase II and Phase III Clinical Trials in Progress. Presentation number and title: CT208 /3 - Final results from a phase 2 trial testing safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wound. Authors: Arshit Narang, MBBS, Prashant Prakash Lad, MD, Shiladitya Sengupta PhD. Tillkännagivande • Mar 26
Vyome Holdings, Inc., Annual General Meeting, Apr 15, 2026 Vyome Holdings, Inc., Annual General Meeting, Apr 15, 2026. Location: sichenzia ross ference carmel llp, 1185 avenue of the americas, 26th floor, ny 10036, new york United States Breakeven Date Change • Mar 25
No longer forecast to breakeven The analyst covering Vyome Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$4.70m in 2028. New forecast suggests the company will make a loss of US$12.0m in 2028. Reported Earnings • Mar 18
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: US$4.75 loss per share. Net loss: US$10.3m (loss widened US$8.81m from FY 2024). Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) missed analyst estimates by 53%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Breakeven Date Change • Dec 31
Forecast to breakeven in 2028 The analyst covering Vyome Holdings expects the company to break even for the first time. New forecast suggests the company will make a profit of US$4.40m in 2028. Average annual earnings growth of 67% is required to achieve expected profit on schedule. Tillkännagivande • Dec 09
Vyome Holdings, Inc. Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval Vyome Holdings, Inc. announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds ("MFW"). VT-1953, a first-in-class immunomodulator for this indication, achieved both its primary and secondary endpoints. With this result, Vyome plans to advance to Phase III pivotal trial, seek FDA approval, and enter the $1B potential addressable market as the only anticipated approved solution for malignant fungating wounds. MFW is a debilitating condition that occurs in 5-14% of advanced cancer patientsi. On a patient-reported Quality of life component score (exploratory endpoint), treatment with VT-1953 resulted in a significant improvement by Day 14 (P=0.002) compared to baseline and vs vehicle-treatment (P=0.0032). New Risk • Nov 19
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$876k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$876k free cash flow). Negative equity (-US$5.0m). Revenue is less than US$1m (US$394k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$1.5m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$26.8m market cap). Reported Earnings • Nov 17
Third quarter 2025 earnings released Third quarter 2025 results: US$3.06 loss per share. Net loss: US$8.43m (loss widened US$7.89m from 3Q 2024). Revenue is forecast to grow 89% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Oct 07
Vyome Holdings, Inc., Annual General Meeting, Oct 28, 2025 Vyome Holdings, Inc., Annual General Meeting, Oct 28, 2025. Location: sichenzia ross ference carmel llp, 1185 avenue of the americas, 31st floor, new york, ny10036, United States Tillkännagivande • Sep 18
Vyome Holdings, Inc. Presents Strong Data Showing Topical VT-1908 Is an Effective Treatment for Uveitis, Opening Up a $3 Billion Addressable Market Opportunity Vyome Holdings, Inc. announced that it's offering is a first-of-its-kind in a broader $20 billion potential addressable ocular inflammation market. VT-1908 eyedrop achieves the desired concentration in the anterior chamber of the eye and significantly reduces uveitis score in preclinical models.Uveitis is a devastating ophthalmic disease, characterized by the inflammation of the uveal tract (iris, ciliary body, and choroid) of the eye. It is a major cause of blindness in both developed and developing countries, and is implicated in causing 30,000 new cases of legal blindness, annually in the United States alone. Anterior uveitis is the most common type of uveitis seen in both adult and pediatric patients, accounting for up to 90% of cases in primary care and 50-60% of cases in tertiary care, with an estimated total of 241,665 cases in the US alone. VT-1953 is a topical formulation of mycophenolate, an IMPDH2 inhibitor. Mycophenolate is approved by the FDA for prophylaxis of organ rejection in adult and pediatric recipients, and has been used off-label to treat uveitis. Vyome has pivoted the systemic use of mycophenolate to a topical formulation optimized for local application to the eye to treat uveitis. The current results of the preclinical studies investigating VT-1908 showed that the desired drug concentration is achieved when applied topically and achieves significant efficacy in a preclinical model of uveitis. Tillkännagivande • Sep 11
Vyome Holdings, Inc. Announces Executive Changes Vyome Holdings, Inc. announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a research and development leader at Catabasis, Pfizer, Sanofi and Gilead. Dr. Fahrner has been involved with the development of more than 17 approved medicines, including Vpriv and Elaprase, which were granted accelerated approvals by the U.S. Food and Drug Administration (USFDA). Dr. Fahrner received his PhD in Biochemistry and Molecular Biology from UCLA. Dr. Agajanov brings nearly 30 years of experience in clinical operations and clinical development, with a focus in oncology, immunology, and inflammation. She has served as SVP of Global Clinical Operations at Neurvati Neurosciences, VP of Clinical Operations at Ovid Therapeutics, Therapeutic Area Head of Oncology at Boehringer Ingelheim, and Associate Director of Immunology, Inflammation and Infectious Disease at Roche. Her leadership has been central to advancing multiple programs through late-stage clinical development. Vyome is currently conducting a Ph2 study in malignant fungating wounds (MFW), a potential multi-billion dollar market opportunity. Topline results from this study are expected by October 2025. Reported Earnings • Sep 08
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: US$50.0k (up 47% from 2Q 2024). Net loss: US$308.8k (loss narrowed 34% from 2Q 2024). Tillkännagivande • Sep 05
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW Market Opportunity Vyome Holdings, Inc. announced the interim results from its investigator-initiated Phase 2 PoC study of VT-1953 topical gel in patients with malignant fungating wounds (MFW). The interim results were first presented at the recent annual meeting of the American Association for Cancer Research. Vyome Co-founder Dr. Shiladitya Sengupta will host a live video conference on Monday, September 8, to share more about the preliminary results and the MFW market in advance of full results, which are expected in October 2026. MFW is a debilitating condition that occurs in 5-14% of advanced cancer patients and it’s estimated that there are over 650,000 patients with advanced cancer in the US, with approximately 10 million patients globally. These numbers were recently confirmed in the latest research published in June 2025. Cancer cells break through the skin and cause a chronic wound (MFW), which is extremely distressing to patients, given the high burden of symptoms, including extreme malodor, severe pain, a feeling of shame, low self-esteem, and social isolation. VT-1953 topical gel is designed to treat the symptoms of MFW by targeting the cause of malodor and inhibiting the drivers of inflammation. In prior clinical studies, VT-1953 topical gel has been well tolerated in over 500 patients. The current results showed encouraging signals of efficacy against symptoms of MFW in both investigator- and patient-reported outcomes. VT-1953, which exerts an immuno-anti-inflammatory effect by targeting TLR-MD2 and DNA gyrase, significantly reduced malodor symptom (P<0.001), as scored by clinical investigators using a TELER Odor scale, the primary endpoint in this interim analysis. Patients also reported a significant reduction in lesion pain scored on a visual analog scale (VAS) (P<0.001) and an improvement in Quality of Life (P<0.001), both secondary and exploratory end points, respectively, in the study. No clinically significant adverse trends were noted with VT-1953 administration. Board Change • Aug 18
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Chairman Krishna Gupta was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
